Philips Takes Cardiac Research to New Heights on Mount Kilimanjaro Climb
05 August 2016 - 10:00PM
Business Wire
Collaboration with Mayo Clinic includes Philips digital
measurement technologies to understand how the body deals with
oxygen deprivation & potential biomarker clues
Royal Philips (NYSE: PHG AEX: PHIA) today announced it will be
among the leading organizations collaborating with the Mayo Clinic
to climb Mount Kilimanjaro on a research expedition to understand
how the body reacts to the rigors of high altitude and how those
learnings can be applied to improving human health. Because the
lack of oxygen at high altitudes mimics oxygen deprivation in the
body during a cardiac event, Philips researchers hope to understand
how to better detect and prevent cardiac issues. The expedition,
which will last about 10 days, starts on August 7 and will be
chronicled on social media through the hashtag #kiliclimb2016.
Mount Kilimanjaro is the highest peak in Africa at nearly 20,000
feet and the highest free standing mountain in the world. As a
leader in digital health technologies, including devices to help
save a life such as automated external defibrillators (AEDs),
Philips researchers hope to use the latest in app-based and digital
technologies to record the vital signs of the nearly 35
participants on the climb, whose ages range from 25 to 65, to find
clues as to how the body adapts to lack of oxygen.
Among the technologies being utilized are:
Contactless monitoring: In many care settings, monitoring
heart rate, arterial blood oxygenation, respiration rate and
activity is a standard part of patient care to detect complications
or deterioration. The current method for measuring these key vital
signs requires the use of sensors on the skin or devices strapped
to the body. Contactless monitoring solutions will offer clinicians
a way to accurately measure vital signs for patients in a
non-obtrusive way, and provide them with the data needed to know
when to intervene. With every heartbeat, the cardiovascular
pressure wave causes tiny ‘micro-blushes’ (small changes in skin
color) in the face. While these changes are not visible to the
human eye,
Philips’ contactless monitoring algorithms can calculate an
accurate pulse rate by quantifying these changes.
Philips CX50 xMATRIX and Lumify ultrasound systems:
Philips portable CX50 xMATRIX is designed to bring premium
ultrasound capability to a variety of care settings. Philips Lumify
is a smart-device, app-based ultrasound designed to help make
ultrasound more accessible. Lumify operates on compatible Android
smart devices equipped with Internet and email functionality. The
Philips CX50 xMATRIX will be used to study heart measurements while
the Lumify will be used for pulmonary measurements, both of which
will help provide researchers with insight on the effects of
hypoxia on human physiology.
Sleep diagnostics: At high altitude1, the lack of
oxygen can impact the body in a number of ways, including increased
work of breathing and heart rate. The Alice NightOne wireless home
sleep testing system will enable the research team to gather data
on sleep quality and possible sleep disturbances from reduced
oxygen content in the blood at high altitudes.
“Cardiology is one of the critical areas of focus for Philips
and as such, we continue to collaborate with industry leaders like
the Mayo Clinic in taking a unique approach to research, which
includes climbing Mount Kilimanjaro to understand how hypoxia, or
lack of oxygen at high elevations, impacts people of different age
groups,” said Carla Kriwet, CEO of Patient Care and Monitoring
Solutions, at Philips. “Hypoxia mimics what happens to the body in
a cardiac event and can give us clues as to how to better diagnose,
treat and prevent these conditions. As we uncover and better
understand the body’s biomarkers and how the body’s mechanisms
acclimate to high altitudes, we can continue to develop
technologies that can make a meaningful impact in the diagnosis and
treatment of cardiovascular care.”
For real-time updates throughout the duration of the climb,
please follow #kiliclimb2016 via @Philips and @PhilipsHealth. For
more information on Philips advanced technologies in cardiology
care, please visit:
http://www.usa.philips.com/healthcare/medical-specialties/cardiology.
About Royal PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA)
is a leading health technology company focused on improving
people’s health and enabling better outcomes across
the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to
deliver integrated solutions. The company is a leader in
diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as
in consumer health and home care.
Headquartered in the Netherlands, Philips’ health technology
portfolio generated 2015 sales of EUR 16.8 billion and employs
approximately 69,000 employees with sales and services in more than
100 countries. News about Philips can be found at
www.philips.com/newscenter.
1 *Philips medical devices being used in this research will be
subject to environmental conditions outside of their normal
operating ranges and performance may vary.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160805005113/en/
Philips Group CommunicationsKathy O’Reilly,
1-978-659-2638kathy.oreilly@philips.comorPhilips North
AmericaSilvie Casanova,
1-978-659-7467silvie.casanova@philips.com
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Apr 2024 to May 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From May 2023 to May 2024